[go: up one dir, main page]

EA200401100A1 - 1α-FTOR-25-HYDROXY-16,23E-DIEN-26,27-BISHOMO-20-EPICHOLOCALTI-SPHEROL AND ITS APPLICATION FOR TREATMENT - Google Patents

1α-FTOR-25-HYDROXY-16,23E-DIEN-26,27-BISHOMO-20-EPICHOLOCALTI-SPHEROL AND ITS APPLICATION FOR TREATMENT

Info

Publication number
EA200401100A1
EA200401100A1 EA200401100A EA200401100A EA200401100A1 EA 200401100 A1 EA200401100 A1 EA 200401100A1 EA 200401100 A EA200401100 A EA 200401100A EA 200401100 A EA200401100 A EA 200401100A EA 200401100 A1 EA200401100 A1 EA 200401100A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bishomo
hydroxy
treatment
spherol
epicholocalti
Prior art date
Application number
EA200401100A
Other languages
Russian (ru)
Other versions
EA010240B1 (en
Inventor
Лучано Адорини
Энрико Колли
Original Assignee
Биокселл Спа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Биокселл Спа filed Critical Биокселл Спа
Publication of EA200401100A1 publication Critical patent/EA200401100A1/en
Publication of EA010240B1 publication Critical patent/EA010240B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Применение 1α-фтор-25-гидрокси-16,23E-диен-26,27-бисгомо-20-эпихолекальциферола, или его фармацевтически приемлемой соли, или сложного эфира для получения лекарственного средства, предназначенного для профилактики и/или лечения доброкачественной гиперплазии предстательной железы (BPH) и ассоциированных симптомов.The use of 1α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epiholecalciferol, or its pharmaceutically acceptable salt, or ester to obtain a drug intended for the prevention and / or treatment of benign prostatic hyperplasia (BPH) and associated symptoms.

EA200401100A 2003-09-24 2004-09-23 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epicholecalciferol and use for treatment thereof EA010240B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment

Publications (2)

Publication Number Publication Date
EA200401100A1 true EA200401100A1 (en) 2005-04-28
EA010240B1 EA010240B1 (en) 2008-06-30

Family

ID=34229055

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401100A EA010240B1 (en) 2003-09-24 2004-09-23 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epicholecalciferol and use for treatment thereof

Country Status (12)

Country Link
EP (1) EP1673096A1 (en)
JP (2) JP2007506699A (en)
CN (1) CN100488511C (en)
BE (1) BE1016292A3 (en)
BR (1) BRPI0404050A (en)
CH (1) CH698144B1 (en)
EA (1) EA010240B1 (en)
FR (1) FR2859910B1 (en)
HK (1) HK1085373A1 (en)
NL (1) NL1027109C2 (en)
NZ (1) NZ535531A (en)
WO (1) WO2005027923A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038611A1 (en) * 2004-10-05 2006-04-13 Kissei Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction
KR20070059152A (en) * 2004-10-06 2007-06-11 깃세이 야쿠힌 고교 가부시키가이샤 Pharmaceutical composition for prevention of transition to surgical therapy for enlarged prostate
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (en) * 2017-03-20 2018-09-21 Pierre Fabre Medicament USE OF COPAIFERA OLEORESIN IN THE PATHOLOGIES OF THE PROSTATE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
CA2289209C (en) * 1997-05-16 2006-07-25 Women & Infants Hospital Cyclic ether vitamin d3 compounds, 1.alpha. (oh) 3-epi-vitamin d3 compounds and uses thereof
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
CN100391464C (en) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 Pharmaceutical compositions comprising active vitamin D compounds

Also Published As

Publication number Publication date
WO2005027923A1 (en) 2005-03-31
CN1615891A (en) 2005-05-18
NL1027109A1 (en) 2005-03-29
NL1027109C2 (en) 2005-05-03
HK1085373A1 (en) 2006-08-25
JP2007506699A (en) 2007-03-22
NZ535531A (en) 2006-03-31
EA010240B1 (en) 2008-06-30
CH698144B1 (en) 2009-05-29
FR2859910A1 (en) 2005-03-25
BRPI0404050A (en) 2005-06-14
EP1673096A1 (en) 2006-06-28
BE1016292A3 (en) 2006-07-04
JP2009035559A (en) 2009-02-19
FR2859910B1 (en) 2006-04-28
CN100488511C (en) 2009-05-20

Similar Documents

Publication Publication Date Title
WO2008046083A3 (en) Use of oxindole compounds as therapeutic agents
EA200401043A1 (en) Treatment of benign prostatic hyperplasia by the selective modulator of the androgen receptor (sarm)
CL2007002953A1 (en) COMPOUNDS DERIVED FROM ESPIRO-OXINDOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF PAIN, CANCER, PRURITE, BENIGN PROSTATIC HYPERPLASIA, HYPERCHOLESTEROLEMIA.
HUP0100586A2 (en) Pharmaceutical compositions treating lower urinary tract symptoms
UY27711A1 (en) USEFUL COMPOUNDS IN THERAPY
ATE518540T1 (en) NEUROTHERAPEUTIC COMPOSITION CONTAINING BETA-LACTAM COMPOUND
DE60223254D1 (en) DELAYED FORCULATING FORMULATIONS OF OXYMORPHONE
DE60327999D1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
DE60218458D1 (en) ISOCHINOLINONE DERIVATIVES AS PARP INHIBITORS
ATE466580T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE468336T1 (en) AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS
ATE365733T1 (en) COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS
WO2008046082A3 (en) Use of heterocyclic compounds as therapeutic agents
EA200501690A1 (en) COMPOSITION INCLUDING PDE4 INHIBITOR AND PDE5 INHIBITOR
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
NO20053042L (en) Use of spongosine (2-methoxyadenosine) for the treatment of pain, especially hyperalgesia.
NO20031648L (en) Pharmaceutical solutions of modafinil compounds
RS92304A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for long-term preservation of acute urinary retention
EA200401100A1 (en) 1α-FTOR-25-HYDROXY-16,23E-DIEN-26,27-BISHOMO-20-EPICHOLOCALTI-SPHEROL AND ITS APPLICATION FOR TREATMENT
TW200503689A (en) Pharmaceutical compositions of atorvastatin
EE05241B1 (en) Use of the α-halogenoacryl derivative of distamycin
EA200200853A1 (en) APPLICATION OF 2-METHYL THIAZOLIDINE-3,3-DICARBONIC ACID (2-MTDK) AND / OR ITS PHYSIOLOGICAL COMPATIBLE SALTS FOR THE TREATMENT AND / OR CANCER PREVENTION
WO2004089379A3 (en) Pharmaceutical combination containing tamsulosin and a non-steroidal anti-inflammatory drug
BG105984A (en) Osanetant in the treatment of mood disorders
GB0301016D0 (en) Treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU